Archive for the ‘Renhuang Pharmaceuticals Inc. RHGP’ Category

Beacon Equity Research Featured Company: Renhuang Pharmaceuticals, Inc. (RHGP.OB)

Monday, January 14th, 2008

Renhuang Pharmaceuticals, Inc. (RHGP.OB)is the market leader in traditional OTC medicines and Acanthopanex-based products. Vertically integrated, Renhuan is a developer, manufacturer and distributor of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products in mainland China. It offers three major product lines: Acanthopanax-based natural medicinal products, the Shark Power healthcare series and Traditional Chinese Medicines.

Renhuang has an established multi-channel research and development infrastructure in China. This infrastructure consists of approximately 50 in-house researchers and engineers, a post-doctoral work center approved and supported by the Chinese government, and collaborations with leading institutions and scientists.

Renhuang is China’s leading supplier of Acanthopanax-based natural medicines and controls 70% of China’s Acanthopanax resource, which is also known as Siberian Ginseng. The Company plans to distribute its products through China’s major drug store chains in urban and suburban markets, through top-tier hospitals and through a multi-layer network consisting of over 2,000 sales agents and 70 sales centers across 24 districts covering over 50% of China. Renhuang also plans to extend its distribution to Russia and Southeast Asia.

In September 2006, Renhuang acquired Harbin Renhuang Pharmaceutical Company Limited. The company later acquired all of the assets of Qingyang Herbal Extracting Factory in March 2007. The acquired Qingyang facility doubles the Company’s current herb extraction capacity and enables processing of approximately 18,000 tons of herbal raw materials. Renhuang strictly adheres to international Good Manufacturing Practices (GMP) production quality standards and has invested in cutting edge technologies.

Renhuang Pharmaceuticals is headquartered in Harbin located within the Heilongjiang Province in Northeast China. China’s demand for health care and pharmaceutical products is expected to rise significantly due to a rapidly growing middle class and an aging population. In addition to growing pharmaceutical needs, herbal medicines remain extremely popular with Chinese consumers and are gaining acceptance with consumers in Western countries as well.

Let us hear your thoughts: Renhuang Pharmaceuticals, Inc. Message Board

Small Cap Voice Featured Company: Renhuang Pharmaceuticals, Inc. (RHGP.OB)

Thursday, December 13th, 2007

Renhuang Pharmaceuticals, Inc. (RHGP.OB) is focused on developing, manufacturing, and distributing high quality natural medicine and bio-pharmaceutical products in China. Currently, the company offers three main product lines: Acanthopanax-based natural medicinal products, the Shark Power healthcare series, and Traditional Chinese Medicines. Sales for each product represent 50%, 20% and 30%, respectively.

Renhuang has also established a multi-channel research and development infrastructure in China. This infrastructure consists of 50 in-house researchers and engineers, a post-doctoral work center supported by the Chinese government, and collaborations with leading institutions and scientists.

Renhuang employs over 2,000 sales agents, and is establishing a strong sales network throughout China. The company has 70 sales centers that extend across 24 districts of China, and cover 50% of the greater China area, including the most populous and developed regions. Rehnuang also has begun to implement a leading marketing strategy focused on increased advertising, variable pricing to increased penetration in non-urban areas.

Let us hear your thoughts: Renhuang Pharmaceuticals, Inc. Message Board

Renhuang Pharmaceuticals, Inc. (RHGP.OB) Rated “Outperform” and Awarded Target Price of $7

Wednesday, November 14th, 2007

Renhuang Pharmaceuticals, Inc has recently been rated as ‘Sector Outperform’ by Beacon Equity Research; and thus, a target price of $7.00 has also been issued.

Renhuang Pharmaceuticals is a leading company focused on manufacturing and distributing a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products in mainland China. The company’s three major product lines consist of: Acanthopanax-based natural medicinal products, the Shark Power healthcare series, and traditional Chinese medicines.

Renhuang, since their initial formation, has been able to successfully establish a leading research and development infrastructure that consists of in-house researchers, a post-doctoral working center, and collaborations with leading institutions and scientists. The Company currently has a portfolio of over 100 products and a presence in more than 50 markets, with much more room for further corporate expansion.

Through various acquisitions, the company is able to expand their global presence directly. Such acquisitions have included Qingyang Pharmaceutical Co. Ltd and Dongfanghong Pharmaceutical Co. The acquisition of Qingyang was momentous for the company, as they were able to process 18,000 tons of herbal raw materials into extracts on a monthly basis. The 2003 acquisition of Dongfanghong Pharmaceutical Co was also critical as Renhuang was able to control over 70% of China’s Acanthopanax resource.

Let us hear your thoughts below: